TNFRSF1B and cardiac hypertrophy: Notably, pathways related to “Inflammation and Immune Response” (e.g., TNFR2 signaling, interleukin signaling, macrophage function), “Cancer and Tumorigenesis” (e.g., molecular mechanisms of cancer, STAT3 signaling), “Growth and Development” (e.g., cardiac hypertrophy, GPCR signaling), and “Metabolic and Lipid Regulation” (e.g., PPAR signaling) showed divergent regulation between the two DEG sets.